Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MBOT 
Microbot Medical Inc (MBOT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MBOT (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -30.23% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 51.77M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1120439 | Beta 1.61 | 52 Weeks Range 0.82 - 3.38 | Updated Date 04/2/2025 |
52 Weeks Range 0.82 - 3.38 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Earnings Date
Report Date 2025-03-25 | When After Market | Estimate -0.18 | Actual -0.2 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -101.21% | Return on Equity (TTM) -284.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 46410269 | Price to Sales(TTM) - |
Enterprise Value 46410269 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.89 | Shares Outstanding 34744500 | Shares Floating 34744476 |
Shares Outstanding 34744500 | Shares Floating 34744476 | ||
Percent Insiders 1.62 | Percent Institutions 7.47 |
Analyst Ratings
Rating 4 | Target Price 8 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Microbot Medical Inc
Company Overview
History and Background
Microbot Medical Inc. was founded in 2010. The company focuses on developing micro-robotic medical technologies, aiming to transform endoluminal surgery. It has faced challenges in bringing its products to market and has experienced periods of financial instability.
Core Business Areas
- Micro-Robotic Medical Devices: Development and commercialization of robotic systems for minimally invasive surgical procedures, particularly focusing on single-use and self-cleaning technologies.
- Liberty Robotic System: The Liberty Robotic System is their core product, designed to allow physicians to navigate and perform procedures remotely in the body's natural lumens.
Leadership and Structure
The leadership team includes Harel Gadot, CEO, and other executives responsible for finance, operations, and technology. The organizational structure consists of departments focused on R&D, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- Liberty Robotic System: The Liberty Robotic System is designed for single-use endoluminal procedures. Microbot Medical is currently in the pre-revenue stage, so market share data is not available. Competitors include Intuitive Surgical (ISRG) with their da Vinci surgical system, Medtronic (MDT) in surgical robotics, and Johnson & Johnson (JNJ) also developing robotic surgery platforms. The company has also been working on tip catheter technology.
Market Dynamics
Industry Overview
The medical robotics industry is experiencing significant growth, driven by demand for minimally invasive procedures, advancements in robotics and imaging technologies, and an aging population. Regulatory hurdles and high development costs are also part of the landscape.
Positioning
Microbot Medical is a relatively small player in a highly competitive market dominated by larger, well-established companies. Its competitive advantage lies in its micro-robotic technology and focus on single-use, self-cleaning devices, but they lack resources and large cash reserves to compete.
Total Addressable Market (TAM)
The global surgical robotics market is projected to reach over $20 billion by 2027. Microbot Medical aims to capture a portion of this market with its Liberty system, targeting specific endoluminal procedures. Given its current size and pre-revenue status, Microbot Medical's current positioning represents a very small fraction of the overall TAM.
Upturn SWOT Analysis
Strengths
- Innovative micro-robotic technology
- Focus on single-use, self-cleaning devices
- Potential to reduce infection risk and procedure time
- Experienced leadership team
Weaknesses
- Limited financial resources
- Pre-revenue stage
- Dependence on regulatory approvals
- Small market capitalization
Opportunities
- Partnerships with larger medical device companies
- Expansion into new therapeutic areas
- Increased adoption of minimally invasive procedures
- Favorable regulatory changes
Threats
- Competition from established players
- Technological obsolescence
- Regulatory delays or rejection
- Economic downturn
Competitors and Market Share
Key Competitors
- ISRG
- MDT
- JNJ
Competitive Landscape
Microbot Medical faces a highly competitive landscape dominated by well-established companies with significant resources. Its advantages include its innovative technology and focus on single-use devices. Disadvantages include its small size, limited financial resources, and dependence on regulatory approvals.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been minimal due to the pre-revenue status. The company's growth trajectory is contingent on achieving regulatory approvals and successfully commercializing its Liberty Robotic System.
Future Projections: Future projections are speculative and depend on successful product launches and market adoption. Analyst estimates vary widely based on assumptions about regulatory timelines and market penetration.
Recent Initiatives: Recent strategic initiatives include securing patents, advancing the Liberty Robotic System through preclinical and clinical trials, and exploring partnerships.
Summary
Microbot Medical is a pre-revenue company with innovative technology in the micro-robotic medical device space. While its technology holds promise, the company faces significant challenges, including limited financial resources, dependence on regulatory approvals, and intense competition from larger, well-established players. The company's success hinges on securing partnerships, obtaining regulatory clearances, and successfully commercializing its Liberty Robotic System. Investors should be aware of the high-risk, high-reward nature of this investment given its pre-revenue status and significant competitive pressures.
Similar Companies
ISRG
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Industry Reports, Analyst Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Microbot Medical Inc
Exchange NASDAQ | Headquaters Braintree, MA, United States | ||
IPO Launch date 1992-03-25 | Co-Founder, President, CEO & Chairman Mr. Harel Gadot | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 20 | Website https://microbotmedical.com |
Full time employees 20 | Website https://microbotmedical.com | ||
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.